EBV, or
Epstein-Barr Virus, is a pretty common and current virus that affects
approximately well over ninety percent of the human adult population. The virus
belongs to the herpes family meaning after the bodies defenses respond to the
initial viral lytic infection, the virus remains latent in B cells till further
proliferation. The virus enters our tonsils after initial transmission via the
saliva1.
Usually, in the
vast majority of infected individuals, virus induced CD8+ T cells
are responsible for the main fight against EBV infection. However, Natural
Killer (NK) cells play an important role for the initial innate immune response
against EBV. This paper, A Distinct Subpopulation of Human
NK Cells Restricts B Cell Transformation by EBV, further explores the abilities of
a specific subpopulation of NK cells in preventing B cell transformation by
EBV. The specific NK subpopulation, known as CD56brightNKG2A+CD94+CD54+CD62L2, was seen by researchers to produce an interestingly
high amount of IFN-γ3. IFN-γ is an important cytokine that is essential for innate
and adaptive immunity when dealing with viral and intracellular bacterial
infections. The importance of IFN-γ in the immune system
stems in part from its ability to inhibit viral replication directly, and most
importantly for its immunostimulatory and immunomodulatory effects.3 So what does this mean?
EBV is fairly common, however,
there is a small subset of EBV infected individuals who due to certain B and
epithelial cell transforming capacity, cause rather serious, detrimental
EBV-associated illnesses1. It is this high interferon gamma producing subpopulation
that the researchers want to focus on in order for future development of cell
based beneficial approaches to EBV associated illness patients.
The goal of the experiments for the
researchers became to see if this specific subpopulation of NK cells truly
produces high amounts of IFN-γ,
in addition to measuring its activity in restricting B cell transformation, and
to determine what about these NK cells make them so superior than others.
To determine the amount of IFN-γ produced by this subpopulation the researchers
stimulated the subpopulation of CD56brightNKG2A+CD94+CD54+CD62L2 for eighteen hours with IL-12; this cytokine is an
important protein that stimulates NK cells to produce IFN-γ2. The
experiment showed that the grand majority of cells were all IFN-γ producing cells. To determine the ability of this
subpopulation to restrict B cell transformation a B cell regression assay was
performed. The assay was carried out by co culturing about a hundred thousand
EBV exposed autologous B cells with different types of tonsilar NK cell as well
as IL-12. The assay showed that the specific subpopulation aforementioned were
4.5 fold more efficient at preventing the outgrowth of EBV infected B cells1.
In conclusion, the researchers did
a great job focusing in on a specific subpopulation of NK cells that had the
incredible phenotype of unusually high IFN-γ production. The experiments performed gave a high amount of confidence that it
is this characteristic that identifies the subpopulation. Specifically, this
paper could shed light on an interesting new type of therapy, NK cell based
transplantation therapies. These therapies have begun to be used by people who
have hematological malignancies, such as leukemia, with a high efficiency of
residual leukemia clearance after chemotherapy4. With such advances
in this field, perhaps this paper can lead to a new type of therapy that could
implant this certain NK subpopulation, CD56brightNKG2A+CD94+CD54+CD62L2, into EBV- associated individuals.
References:
Primary article:
1.) Tarik Azzi, Anna Lunemann,
Christian Munz, David Nadal, Liliana D. Vanoaica. 2013. A Distinct Subpopulation of
Human NK Cells Restricts B Cell Transformation by EBV. Journal of Immunology. 109: 4989-4995.
Other
Articles:
2.) Fehniger,
T. A., M. A. Cooper, G. J. Nuovo, M. Cella, F. Facchetti, M. Colonna, and M. A.
Caligiuri. 2003. CD56bright natural killer cells are present in human lymph
nodes and are activated by T cell-derived IL-2: a potential new link be- tween
adaptive and innate immunity. Blood 101: 3052–3057.
3.) Strowig, T., F. Brilot, F. Arrey, G.
Bougras, D. Thomas, W. A. Muller, and C. Mu ̈nz. 2008. Tonsilar NK cells
restrict B cell transformation by the Epstein- Barr virus via IFN-g. PLoS
Pathog. 4: e27.
4.) Curti,
A., L. Ruggeri, A. D’Addio, A. Bontadini, E. Dan, M. R. Motta, S. Trabanelli,
V. Giudice, E. Urbani, G. Martinelli, et al. 2011. Successful transfer of
alloreactive haploidentical KIR ligand-mismatched natural killer cells after
infusion in elderly high risk acute myeloid leukemia patients. Blood 118:
3273–3279.
No comments:
Post a Comment